Bright Net Debt from 2010 to 2026

DRUG Stock  USD 80.30  3.61  4.30%   
Bright Minds' Net Debt is decreasing over the last several years with slightly volatile swings. Net Debt is estimated to finish at about -70.8 M this year. Net Debt is the total debt of Bright Minds Biosciences minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals
 
Net Debt  
First Reported
2019-12-31
Previous Quarter
-51.2 M
Current Value
-82.8 M
Quarterly Volatility
22.1 M
 
Covid
 
Interest Hikes
Check Bright Minds financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bright Minds' main balance sheet or income statement drivers, such as Depreciation And Amortization of 60.3 K, Interest Expense of 49.2 K or Selling General Administrative of 1.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.73. Bright financial statements analysis is a perfect complement when working with Bright Minds Valuation or Volatility modules.
  
Build AI portfolio with Bright Stock
Check out the analysis of Bright Minds Correlation against competitors.
The Net Debt trend for Bright Minds Biosciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Bright Minds is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Bright Minds' Net Debt Growth Pattern

Below is the plot of the Net Debt of Bright Minds Biosciences over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Bright Minds' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bright Minds' overall financial position and show how it may be relating to other accounts over time.
Net Debt10 Years Trend
Slightly volatile
   Net Debt   
       Timeline  

Bright Net Debt Regression Statistics

Arithmetic Mean(16,065,299)
Coefficient Of Variation(181.64)
Mean Deviation21,595,937
Median(79,991)
Standard Deviation29,181,634
Sample Variance851.6T
Range82.7M
R-Value(0.73)
Mean Square Error429.9T
R-Squared0.53
Significance0.001
Slope(4,193,801)
Total Sum of Squares13625.1T

Bright Net Debt History

2026-70.8 M
2025-74.5 M
2024-82.8 M
2023-5.6 M
2022-6.7 M
2021-11.5 M
2020-19.8 M

Other Fundumenentals of Bright Minds Biosciences

Bright Minds Net Debt component correlations

1.00.54-0.99-0.690.950.961.0-0.580.97-0.791.00.991.00.97-0.840.88-0.79
1.00.58-0.99-0.710.950.961.0-0.610.97-0.781.00.991.00.96-0.830.87-0.78
0.540.58-0.57-0.760.640.620.54-0.840.67-0.270.530.60.530.36-0.510.46-0.27
-0.99-0.99-0.570.71-0.94-0.95-0.990.6-0.960.68-0.99-0.97-0.99-0.950.84-0.910.68
-0.69-0.71-0.760.71-0.77-0.78-0.690.83-0.850.46-0.69-0.8-0.69-0.550.78-0.640.46
0.950.950.64-0.94-0.771.00.95-0.70.96-0.730.940.960.940.92-0.80.81-0.73
0.960.960.62-0.95-0.781.00.96-0.680.97-0.740.960.970.960.93-0.820.83-0.74
1.01.00.54-0.99-0.690.950.96-0.580.97-0.791.00.991.00.97-0.840.88-0.79
-0.58-0.61-0.840.60.83-0.7-0.68-0.58-0.720.37-0.57-0.66-0.57-0.430.58-0.490.37
0.970.970.67-0.96-0.850.960.970.97-0.72-0.750.960.990.960.89-0.870.85-0.75
-0.79-0.78-0.270.680.46-0.73-0.74-0.790.37-0.75-0.79-0.77-0.79-0.80.6-0.51.0
1.01.00.53-0.99-0.690.940.961.0-0.570.96-0.790.981.00.97-0.840.88-0.79
0.990.990.6-0.97-0.80.960.970.99-0.660.99-0.770.980.980.93-0.880.88-0.77
1.01.00.53-0.99-0.690.940.961.0-0.570.96-0.791.00.980.97-0.840.88-0.79
0.970.960.36-0.95-0.550.920.930.97-0.430.89-0.80.970.930.97-0.770.86-0.8
-0.84-0.83-0.510.840.78-0.8-0.82-0.840.58-0.870.6-0.84-0.88-0.84-0.77-0.860.6
0.880.870.46-0.91-0.640.810.830.88-0.490.85-0.50.880.880.880.86-0.86-0.5
-0.79-0.78-0.270.680.46-0.73-0.74-0.790.37-0.751.0-0.79-0.77-0.79-0.80.6-0.5
Click cells to compare fundamentals

About Bright Minds Financial Statements

Bright Minds stakeholders use historical fundamental indicators, such as Bright Minds' Net Debt, to determine how well the company is positioned to perform in the future. Although Bright Minds investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bright Minds' assets and liabilities are reflected in the revenues and expenses on Bright Minds' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bright Minds Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Debt-74.5 M-70.8 M
Net Debt To EBITDA 6.15  6.46 

Currently Active Assets on Macroaxis

When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:
Check out the analysis of Bright Minds Correlation against competitors.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Can Biotechnology industry sustain growth momentum? Does Bright have expansion opportunities? Factors like these will boost the valuation of Bright Minds. Projected growth potential of Bright fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Bright Minds demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(2.03)
Return On Assets
(0.16)
Return On Equity
(0.27)
Bright Minds Biosciences's market price often diverges from its book value, the accounting figure shown on Bright's balance sheet. Smart investors calculate Bright Minds' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Bright Minds' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bright Minds' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bright Minds should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.